Prescribing All Phosphodiesterase 5 Inhibitors to a Patient with Erectile Dysfunction—A Realistic
Saturday, 06 May 2006
Objective
In clinical practice, to apply and evaluate outcomes of a treatment regime, in which the patient had the opportunity to try all the available phosphodiesterase 5 (PDE5) inhibitors.
read more
|
European Urology - Optimisation of PDE5 Inhibitor Therapy in Men with Erectile Dysfunction: Converting “Non-Responders” into “Responders”
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 31-33 (July 2006) The first line therapy for most men with erectile dysfunction is currently a phosphodiesterase type 5 (PDE5) inhibitor such as sildenafil, tadalafil, or vardenafil.
read more
|
European Urology - The Metabolic Syndrome and Erectile Dysfunction: Multiple Vascular Risk Factors and Hypogonadism
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 426-427 (September 2006) In this issue Corona and colleagues conclude that erectile dysfunction (ED) is more severe in patients with the metabolic syndrome and associated with an increased incidence of hypogonadism [1]. The findings have important lifestyle, prevention, and therapeutic implications.
read more
|
European Urology - Vardenafil Duration of Action
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 901-902 (November 2006) Article Outline: The time we spend with a patient explaining how to use a phosphodiesterase type 5 inhibitor (PDE5-I) and the quality of the information we provide are recognised as important factors that contribute to the success of the treatment.
read more
|
Evaluating Preference Trials of Oral Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Monday, 02 January 2006
Volume 49, Issue 1, Pages 30-37 (January 2006) Abstract - More treatment options are available now for the treatment of erectile dysfunction (ED) than ever. Treatments include oral phosphodiesterase 5 (PDE5) inhibitors, intracavernosal injections, vacuum constriction devices, and penile implants. Clinicians, researchers, and patients are interested in making direct comparisons between the response of newer treatments and that of established and more developed therapies.
read more
|
European Urology - Salvage Techniques for Phosphodiesterase 5 Inhibitor Therapy: Purposeful but How Much?
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 29-30 (July 2006) Several studies have confirmed that non-responders to the phosphodiesterase 5 (PDE5) inhibitor sildenafil for the treatment of erectile dysfunction (ED) can be “salvaged” with various strategies including reinstruction in using the medication and application of drug treatment optimisation techniques.
read more
|
European Urology - Positive Effect of Counseling and Dose Adjustment in Patients with Erectile Dysfunction who Failed Treatment with Sildenafil
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 134-140 (July 2006) 1. Introduction Sildenafil citrate, a potent and selective inhibitor of phosphodiesterase type 5 in the penile corpus cavernosum, is a highly effective treatment for ED [1].
read more
|
European Urology - Psychobiologic Correlates of the Metabolic Syndrome and Associated Sexual Dysfunction
Wednesday, 06 September 2006
Volume 50, Issue 3, Pages 595-604 (September 2006) 1. Introduction: A worldwide epidemic increase in obesity has occurred in recent decades and will steadily increase in the near future, due to substantial lifestyle changes [1].
read more
|
European Urology - Treatment Strategy for “Non-Responders” to Tadalafil and Vardenafil: A Real-Life Study
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 126-133 (July 2006) 1. Introduction Phosphodiesterase type 5 (PDE5) inhibitors are today the first treatment option of erectile dysfunction (ED) among physicians and patients [1].
read more
|
European Urology - The Evolution of ED Therapy in the 21st Century
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1157-1159 (December 2006) Article Outline: Great strides have been achieved in our understanding of the physiology of erectile dysfunction (ED) and the potential for therapeutics over the past two decades [1], [2].
read more
|
European Urology - Unexpected Insights into Pelvic Function Following Phosphodiesterase Manipulation—What's Next for Urology?
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1153-1156 (December 2006) Article Outline: The review article concerning phosphodiesterases (PDEs) submitted by Ückert et al. is both excellent and comprehensive in its evaluation of the PDE isoenzymes and their potential role in various urologic settings [1].
read more
|
European Urology - Erectile Dysfunction and Vascular Risk: Let's Get It Right
Wednesday, 20 September 2006
Volume 50, Issue 4, Pages 660-661 (October 2006) The current consensus is that erectile dysfunction (ED) and vascular disease often coexist and that endothelial dysfunction is the common denominator [1].
read more
|
European Urology - Rationale for Androgens and Erectile Dysfunction in 2006
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 898-900 (November 2006) Article Outline: Erectile function (EF) is a critical and complex neurovascular process mediated by several biochemical and physiologic factors.
read more
|
European Urology - Sulcus Nervi Dorsalis Penis/Clitoridis: Anatomic Structure and Clinical Significance
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1079-1085 (November 2006) Abstract - Objectives: The aim of this study was to correlate the anatomic and clinical significance of the prepubic course of dorsal nerve of penis and its groove on the pubic bone from the perspective of the surgeon.
read more
|
Penile Suspensory Ligament Division for Penile Augmentation: Indications and Results
Monday, 03 April 2006
Objective: This study assessed the management of patients requesting penile length enhancement by division of the penile suspensory ligament.
read more
|
EAU Guidelines on Erectile Dysfunction: An Update
Saturday, 06 May 2006
The introduction of new oral therapies has completely changed the diagnostic and therapeutic approach to erectile dysfunction. A panel of experts in this field has developed guidelines for the clinical evaluation and treatment based on the review of available scientific information.
read more
|
European Urology - Extended Duration of Efficacy of Vardenafil When Taken 8 Hours Before Intercourse: A Randomized, Double-Blind, Placebo-Controlled Study
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1086-1095 (November 2006) 1. Introduction - It has been estimated that >150 million men worldwide experience erectile dysfunction (ED) and that its prevalence is likely to rise with the ageing population [1], [2].
read more
|
European Urology - Peyronie's Disease: Can We Prevent Disease Progression?
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 946-947 (June 2006) Peyronie's disease is caused by an inflammatory process of the tunica albuginea of unknown origin that may result in painful erections, palpable indurations and penile shortening.
read more
|
European Urology - Female Sexual Dysfunction after Pelvic Surgery: Is There a Place for Nerve-Sparing Surgery?
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 14-16 (July 2006)
The review by Salonia et al. [1] raises an interesting new and neglected topic in urologic surgery—preservation of sexual function in women following urogynaecologic and oncologic pelvic surgical procedures.
read more
|
European Urology - Type 5 Phosphodiesterase Inhibitors: Curing Erectile Dysfunction
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 942-945 (June 2006) Basic science research on erectile physiology has focused on the pathogenesis of erectile dysfunction (ED) and has provided convincing evidence that ED is predominately a disease of vascular etiology correlating with coronary artery disease, hypertension, atherosclerosis, hyperlipidemia, smoking, and diabetes mellitus [1], [2].
read more
|
New Perspectives of Penile Enhancement Surgery: Tissue Engineering with Biodegradable Scaffolds
Monday, 02 January 2006
Objective: To evaluate in a multicenter, prospective study preliminary aesthetic and functional results of autologous ex-vivo tissue engineering for penile girth enhancement.
read more
|
European Urology - Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Wednesday, 19 July 2006
Volume 50, Issue 2, Pages 351-359 (August 2006) 1. Introduction: Medical management of erectile dysfunction (ED) changed with the observation in 1992 that the nitric oxide-cyclic GMP pathway plays a critical role in erectile function (EF) and defects in this pathway may cause some forms of ED [1].
read more
|
Evaluating Preference Trials of Oral Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Monday, 02 January 2006
More treatment options are available now for the treatment of erectile dysfunction (ED) than ever. Treatments include oral phosphodiesterase 5 (PDE5) inhibitors, intracavernosal injections, vacuum constriction devices, and penile implants. Clinicians, researchers, and patients are interested in making direct comparisons between the response of newer treatments and that of established and more developed therapies.
read more
|
European Urology - Women's Sexual Dysfunction: A Review of the “Surgical Landscape”
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 44-52 (July 2006) 1. Introduction: Sexual dysfunction (SD) in women has been defined as a multifactorial condition with anatomic, physiologic, medical, psychological, and social components.
read more
|
European Urology - A Critical Analysis of Nonsurgical Treatment of Peyronie's Disease
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 987-997 (June 2006)
1. IntroductionPeyronie's disease is characterized by the clinical symptoms of penile pain, a plaque of the tunica albuginea, and penile curvature.
read more
|
European Urology - Gene Therapy for Erectile Dysfunction: Fact or Fiction?
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1208-1222 (December 2006) 1. Introduction Basic science research on erectile physiology has focused on the pathogenesis of erectile dysfunction (ED) and has provided convincing evidence that ED is predominately a disease of vascular etiology [1].
read more
|
European Urology - Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction?
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 979-986 (June 2006)
1. Introduction Erectile dysfunction (ED) is a common medical condition that affects millions of men.
read more
|
European Urology - Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and Future
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1194-1207 (December 2006) 1. IntroductionThe cyclic nucleotide monophosphates (cNMPs) cAMP and cGMP are important intracellular regulators of several processes, including smooth muscle motility, electrolyte homeostasis, neuroendocrine signals and retinal phototransduction [1], [2].
read more
|
European Urology - Association between Erectile Dysfunction and Coronary Artery Disease: Matching the Right Target with the Right Test in the Right Patient
Thursday, 21 September 2006
Volume 50, Issue 4, Pages 721-731 (October 2006) 1. Introduction Erectile dysfunction (ED) is defined as the inability to reach or maintain erection sufficient for satisfactory sexual performance. Evidence is accumulating in favour of ED as a vascular disorder in the majority of patients.
read more
|
